GSK 3377794

Drug Profile

GSK 3377794

Alternative Names: GSK-3377794; NY-ESO SPEAR T-cell therapy; NY-ESO TCR therapeutic; NY-ESO-1 T cell receptor; NY-ESO-1-specific T-cells - Adaptimmune; NY-ESO-1/LAGE-1-modified T-cells; NY-ESO-1c259T; NY-ESO-c259T

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adaptimmune
  • Developer Adaptimmune; GlaxoSmithKline; Merck & Co
  • Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Synovial sarcoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Gastrointestinal cancer; Malignant melanoma; Multiple myeloma; Ovarian cancer
  • Phase I/II Liposarcoma; Non-small cell lung cancer; Synovial sarcoma
  • No development reported Liver cancer; Prostate cancer

Most Recent Events

  • 15 Mar 2018 Efficacy data from a phase I/II trial in Liposarcoma released by Adaptimmune
  • 11 Dec 2017 Adverse events and efficacy data from a phase I/II pivotal trial in Multiple myeloma presented at the American Society of Hematology Annual Meeting (ASH-2017)
  • 05 Dec 2017 Updated efficacy and adverse events data from a phase I/II trial in Multiple myeloma released by Adaptimmune
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top